BR9814370A - Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga. - Google Patents
Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga.Info
- Publication number
- BR9814370A BR9814370A BR9814370-0A BR9814370A BR9814370A BR 9814370 A BR9814370 A BR 9814370A BR 9814370 A BR9814370 A BR 9814370A BR 9814370 A BR9814370 A BR 9814370A
- Authority
- BR
- Brazil
- Prior art keywords
- recombinant
- fusion protein
- protein
- rhabdovirus
- heterologous fusion
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6847297P | 1997-12-22 | 1997-12-22 | |
| PCT/US1998/026084 WO1999032648A1 (en) | 1997-12-22 | 1998-12-22 | Recombinant rhabdovirus containing a heterologous fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9814370A true BR9814370A (pt) | 2000-10-10 |
Family
ID=22082797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9814370-0A BR9814370A (pt) | 1997-12-22 | 1998-12-22 | Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6497873B1 (enExample) |
| EP (1) | EP1040198B1 (enExample) |
| JP (1) | JP4544497B2 (enExample) |
| AP (1) | AP1968A (enExample) |
| AT (1) | ATE451466T1 (enExample) |
| AU (2) | AU752004B2 (enExample) |
| BR (1) | BR9814370A (enExample) |
| CA (1) | CA2316033A1 (enExample) |
| DE (1) | DE69841372D1 (enExample) |
| IL (2) | IL136905A0 (enExample) |
| MX (1) | MXPA00006184A (enExample) |
| NZ (1) | NZ505312A (enExample) |
| OA (1) | OA11432A (enExample) |
| WO (1) | WO1999032648A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1044708B (en) * | 1999-09-17 | 2006-10-27 | Wellstat Biologics Corporation | Oncolytic vesicular stomatitis virus |
| AU2001281151A1 (en) * | 2000-08-24 | 2002-03-04 | Thomas Jefferson University | Rhabdovirus-based vectors to express high levels of functional human antibodies |
| EP1421222A4 (en) * | 2001-03-09 | 2004-07-07 | Univ California | CELL CULTURE SYSTEM FOR SYNTHESIS OF INFECTIOUS HEPATITIS-C VIRUS |
| US20030044386A1 (en) * | 2001-07-11 | 2003-03-06 | Barber Glen N. | Recombinant VSV for the treatment of tumor cells |
| US7820435B2 (en) * | 2002-02-06 | 2010-10-26 | Expression Technologies Inc. | De novo synthesized plasmid, methods of making and use thereof |
| US7731974B2 (en) * | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| ES2319424T3 (es) | 2003-03-27 | 2009-05-07 | Ottawa Health Research Institute | Virus mutantes de la estomatitis vesivular y sus usos. |
| DK1629004T3 (da) * | 2003-06-05 | 2008-11-17 | Wyeth Corp | Immunogene sammensætninger indeholdende venezuelansk hesteencephalitisvirus-replikonvektorer og paramyxovirus-proteinantigener |
| MXPA05013141A (es) | 2003-06-09 | 2006-03-17 | Wyeth Corp | Metodo mejorado para la recuperacion de arn virus de cadena negativa, no segmentados, a partir de adnc. |
| CA2921063C (en) * | 2006-09-15 | 2020-01-28 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| US8703469B2 (en) | 2007-07-06 | 2014-04-22 | Boyce Thompson Institute For Plant Research | Baculoviruses with enhanced virion production and a method for the production of baculoviruses |
| WO2009014878A2 (en) * | 2007-07-06 | 2009-01-29 | Boyce Thompson Institute For Plant Research | Baculoviruses with enhanced virion production and a method for the production of baculoviruses |
| AU2010215872A1 (en) | 2009-02-20 | 2011-09-01 | International Aids Vaccine Initiative | Vesicular stomatitis virus vectors encoding HIV Env epitopes |
| US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
| JP2015514420A (ja) | 2012-04-18 | 2015-05-21 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 複製可能な水疱性口内炎ウイルス |
| FR2996856B1 (fr) * | 2012-10-15 | 2015-06-05 | Agronomique Inst Nat Rech | Novirhabdovirus recombinant utilisable comme vecteur d'antigenes |
| EP3619299A1 (en) * | 2017-05-03 | 2020-03-11 | BioMarin Pharmaceutical Inc. | Improved lentiviruses for transduction of hematopoietic stem cells. |
| IL263979B2 (en) | 2017-05-10 | 2023-09-01 | Wellstat Immuno Therapeutics Llc | Viruses with an envelope resistant to the immune system for cancer treatment |
| CN115768784A (zh) * | 2020-02-06 | 2023-03-07 | 勃林格殷格翰动物保健有限公司 | 用于检测抗弹状病毒抗体的多肽 |
| WO2023051607A1 (zh) * | 2021-09-29 | 2023-04-06 | 上海行深生物科技有限公司 | 病毒培养方法 |
-
1998
- 1998-12-22 JP JP2000525566A patent/JP4544497B2/ja not_active Expired - Fee Related
- 1998-12-22 WO PCT/US1998/026084 patent/WO1999032648A1/en not_active Ceased
- 1998-12-22 DE DE69841372T patent/DE69841372D1/de not_active Expired - Lifetime
- 1998-12-22 CA CA002316033A patent/CA2316033A1/en not_active Abandoned
- 1998-12-22 BR BR9814370-0A patent/BR9814370A/pt not_active Application Discontinuation
- 1998-12-22 NZ NZ505312A patent/NZ505312A/xx unknown
- 1998-12-22 AP APAP/P/2000/001852A patent/AP1968A/en active
- 1998-12-22 AU AU19056/99A patent/AU752004B2/en not_active Ceased
- 1998-12-22 MX MXPA00006184A patent/MXPA00006184A/es not_active IP Right Cessation
- 1998-12-22 IL IL13690598A patent/IL136905A0/xx active IP Right Grant
- 1998-12-22 EP EP98963811A patent/EP1040198B1/en not_active Expired - Lifetime
- 1998-12-22 AT AT98963811T patent/ATE451466T1/de not_active IP Right Cessation
- 1998-12-22 US US09/217,967 patent/US6497873B1/en not_active Expired - Fee Related
-
2000
- 2000-06-20 IL IL136905A patent/IL136905A/en not_active IP Right Cessation
- 2000-06-21 OA OA1200000184A patent/OA11432A/en unknown
-
2002
- 2002-07-19 AU AU2002300207A patent/AU2002300207B2/en not_active Ceased
- 2002-10-23 US US10/277,997 patent/US20030138457A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1040198A1 (en) | 2000-10-04 |
| IL136905A0 (en) | 2001-06-14 |
| DE69841372D1 (de) | 2010-01-21 |
| ATE451466T1 (de) | 2009-12-15 |
| AU2002300207B2 (en) | 2006-07-13 |
| AP2000001852A0 (en) | 2000-06-30 |
| AU752004B2 (en) | 2002-09-05 |
| MXPA00006184A (es) | 2003-02-11 |
| US20030138457A1 (en) | 2003-07-24 |
| AP1968A (en) | 2009-04-30 |
| IL136905A (en) | 2007-10-31 |
| EP1040198B1 (en) | 2009-12-09 |
| WO1999032648A1 (en) | 1999-07-01 |
| CA2316033A1 (en) | 1999-07-01 |
| AU1905699A (en) | 1999-07-12 |
| US6497873B1 (en) | 2002-12-24 |
| OA11432A (en) | 2004-04-26 |
| JP4544497B2 (ja) | 2010-09-15 |
| NZ505312A (en) | 2003-01-31 |
| JP2001526901A (ja) | 2001-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9814370A (pt) | Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga. | |
| CO2020001113A2 (es) | Muteínas de interleucina 21 y métodos de tratamiento | |
| ATE352559T1 (de) | Verfahren zur verminderung der immunogenität von proteinen | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| ES2147553T3 (es) | Vectores virales recombinantes para la expresion en unas celulas musculares. | |
| DE60238472D1 (de) | Abschwächung der immunogenizität von fusionsproteinen | |
| BR0007840A (pt) | Proteìnas de fusão her-2/neu | |
| AR093626A1 (es) | Proteinas de fusion de enzima lisosomal y usos de las mismas | |
| DK382786D0 (da) | Overfladeaktivt rekombinant-alveolarprotein | |
| CO6231039A2 (es) | Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas | |
| AR059371A1 (es) | Terapia genica para la enfermedad de niemann-pick tipo a | |
| MY200710A (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| BR9816013A (pt) | Proteìna de ligação de interleucina-18 | |
| ES545760A0 (es) | Procedimiento para preparar peptidos liberadores de la hormona del crecimiento. | |
| BR112022010321A2 (pt) | Composições e métodos para tratamento de neuropatia óptica hereditária de leber com proteínas nadh desidrogenase | |
| AR013529A1 (es) | Rantes amino-terminalmente truncado, moleculas de adn, vector de expresion, celula huesped, proceso recombinante para prepararlo, su uso para preparar un medicamento y composicion farmaceutica que lo comprende. | |
| DE60036537D1 (de) | Zusammensetzungen zur gentherapie von diabetes | |
| BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
| DE69529750D1 (de) | Verbesserungen in der herstellung von proteinen in wirtszellen | |
| BR0303362A (pt) | Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal | |
| AR019851A1 (es) | Proteina sustancialmente pura con actividad similar a scarface 3 in vivo o in vitro; analogos de proteina scarface 3; aislados de compuestos de acidosnucleicos que codifican dichas proteinas; vectores que incluyen dichos compuestos de acidos nucleicos; celulas huespedes que poseen dichos vectores yf | |
| DK0811068T3 (da) | Humane DNase I varianter | |
| MX2024013887A (es) | Composiciones que comprenden interleucina-33 truncada e interleucina-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |